Topical delivery of a human single-domain antibody targeting IL-33 to inhibit mucosal inflammation
Keke Huang(Central South University), Jiaxu Hong(Eye & ENT Hospital of Fudan University), Wenping Song(Zhengzhou University), Zhenlin Yang(Fudan University), Cheng Li(Shanghai Medical College of Fudan University), Yuqing Wu(Zhejiang University), Tianlei Ying(Shanghai Medical College of Fudan University), Xujiao Zhou(Fudan University), Yu Kong(Fudan University), Xiaoyi Zhu(Shanghai Medical College of Fudan University), Yanling Wu(Shanghai Medical College of Fudan University), Quanxiao Li(Suzhou Research Institute), Yirou Zhang(Eye & ENT Hospital of Fudan University), Changchang Xin(Fudan University)
Cited by 8
Related Papers
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Identification of Human Single-Domain Antibodies against SARS-CoV-2
|Cell Host & Microbe|2020|283
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
|Signal Transduction and Targeted Therapy|2020|213
Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice
|Nature Biotechnology|2021|186
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection
|Cell Reports|2020|164